Clinical Trial

A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy and safety of HRS-7249 for patients with hyperlipidemia, and to explore the reasonable dosage of HRS-7249 for patients with hyperlipidemia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-27; most recent amendment 2026-06-02.
Status change: Recruiting → Active, Not Recruiting 2026-06-02
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT07100418
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Hyperlipidemia
Enrollment 224 participants
Start Date 2025-08-12
Primary Completion 2026-09 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03